drugset
drugset / Trial / NCT04730804

A Study of ALXN1830 in Healthy Adult Participants

NCT04730804 ↗

Phase 1 Terminated 34 enrolled Alexion Pharmaceuticals, Inc. Syneos Health · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

This trial will study the effects of single and multiple doses of ALXN1830 in healthy adult participants.

Timeline

Start
2021-03-17
Primary completion
2021-12-14
Completion
2022-01-04

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to terminate program”

Drugs

EvaluationDrugModalityDoseRoute
Subject ORILANOLIMAB Monoclonal antibody — Subcutaneous

Indications

No indication recorded.